Communiqués Bristol-Myers Squibb Company Lima

Actions

BMYUS

US1101221083

Produits pharmaceutiques

Temps réel estimé Cboe BZX Autres places de cotation 02:00:00 28/07/2026			Varia. 5j.	Varia. 1 janv.
81,96 ^USD	+36,24%		+1,38%	+11,70%

09:02	Medincell continue de renforcer son conseil d'administration
27/07	Échec clinique pour le traitement de la schizophrénie de MapLight, l'action s'effondre	RE

Communiqués

20/07	Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA	BU
13/07	U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma	BU
18/06	Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026	BU
17/06	Bristol Myers Squibb Announces Dividend	BU
08/06	Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease	BU
02/06	Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma	BU
01/06	U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)	BU
01/06	Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma	BU
29/05	Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma	BU
27/05	Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference	BU
21/05	Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline	BU
20/05	Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations	BU
15/05	Employers Gain As Second Circuit Restricts Out-of-State Plaintiffs From Joining FLSA Collective Actions	AQ
08/05	Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults	BU
06/05	Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026	BU
04/05	Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™	BU
30/04	Bristol Myers Squibb : Q1 2026 Results Presentation with Appendix	PU
30/04	Bristol Myers: Q1 Earnings Snapshot	AQ
30/04	Bristol Myers Squibb Reports First Quarter Financial Results for 2026	BU
27/04	Bristol Myers Squibb and Pfizer to Make Eliquis Available via Mark Cuban Cost Plus Drug Company	AQ
24/04	Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company	BU
23/04	Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration	PR
08/04	MIT: Researchers develop molecular editing tool to relocate alcohol groups	AQ
07/04	Leadership In The Law: Fireside Chat With Cari Gallman, Executive Vice President, General Counsel And Chief Policy Officer At Bristol Myers Squibb (Video)	AQ
03/04	Bristol Myers Squibb : Preliminary Q1 2026 Acquired IPRD & Licensing Income	PU